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BACKGROUND: Identification of tumour-associated antigens (TAAs) that induce cytotoxic T lymphocytes (CTLs) specific to cancer cells
is critical for the development of anticancer immunotherapy. In this study, we aimed at identifying a novel TAA of pancreatic cancer
for immunotherapy.
METHODS: On the basis of the genome-wide cDNA microarray analysis, we focused on KIF20A (also known as RAB6KIFL/MKlp2) as a
candidate TAA in pancreatic cancer cells. The HLA-A2 (A*02:01)-restricted CTL epitopes of KIF20A were identified using HLA-A2
transgenic mice (Tgm) and the peptides were examined to check whether they could generate human CTLs exhibiting cytotoxic
responses against KIF20A
þ, HLA-A2
þ tumour cells in vitro.
RESULTS: KIF20A was overexpressed in pancreatic cancer and in some other malignancies, but not in their non-cancerous counterparts
and many normal adult tissues. We found that KIF20A-2 (p12–20, LLSDDDVVV), KIF20A-8 (p809–817, CIAEQYHTV), and
KIF20A-28 (p284–293, AQPDTAPLPV) peptides could induce HLA-A2-restricted CTLs in HLA-A2 Tgm without causing
autoimmunity. Peptide-reactive human CTLs were generated from peripheral blood mononuclear cells of HLA-A2
þ healthy donors
by in vitro stimulation with the three peptides, and those CTLs successfully exhibited cytotoxic responses to cancer cells expressing
both KIF20A and HLA-A2.
CONCLUSION: KIF20A is a novel promising candidate for anticancer immunotherapeutic target for pancreatic cancers.
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Pancreatic cancer is one of the highly lethal malignancies with an
overall 5-year survival rate of B5% (Jemal et al, 2007). Although a
surgical resection is the only treatment for long-term survival,
patients with resectable pancreatic cancer are in the minority
(9–22%) (Eloubeidi et al, 2006; Goonetilleke and Siriwardena,
2007). Furthermore, even the 5-year survival rate after a curative
resection is reported to be B20% (Cleary et al, 2004; Smeenk et al,
2005; Moon et al, 2006). Therefore, there is a strong need for
development of novel therapeutic modalities.
Anticancer immunotherapy is considered to be the candi-
date modality for pancreatic cancer. Recently, analyses of gene
expression profiles of cancer and normal cells using cDNA
microarray technologies have provided an effective approach
for the identification of tumour-associated antigens (TAAs)
(Nakatsura et al, 2004b; Uchida et al, 2004; Yoshitake et al, 2004;
Watanabe et al, 2005; Komori et al, 2006; Suda et al, 2006;
Harao et al, 2008; Imai et al, 2008). This study analysed the gene
expression profiles of pancreatic cancer using a genome-wide
cDNA microarray consisting of 27648 genes, which revealed that
KIF20A was overexpressed in pancreatic cancer tissues but not in
many normal tissues.
In this study, we examined whether KIF20A could be a potential
target for anticancer immunotherapy. To this aim, human KIF20A-
derived and HLA-A2-restricted cytotoxic T lymphocyte (CTL)
epitopes were identified using HLA-A2 transgenic mice (Tgm), and
the ability of peptides to induce KIF20A-reactive human CTLs that
kill cancer cells and the safety not to induce autoimmune
responses in the mouse were investigated.
MATERIALS AND METHODS
cDNA microarray analysis
A data set of genome-wide cDNA microarray analyses using
cancerous and adjacent normal tissues obtained by a laser
microbeam dissection (Nakamura et al, 2004) was used in this
study. The tissue samples were obtained from surgical specimens
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sof pancreatic cancer patients. All patients provided their written
informed consent to participate in this study.
Mice, cell lines, and HLA expression
The HLA-A2 Tgm, H-2D
b /  b2m
 /  double knockout mice
introduced with a monochain gene construct of human b2m-
HLA-A2.1(a1, a2)-H-2D
b(a3, transmembrane, and cytoplasmic)
(Pascolo et al, 1997; Firat et al, 1999), were kindly provided by
Dr FA Lemonnier. Mice were maintained and handled in accordance
with the animal care guidelines of the Kumamoto University.
The human pancreatic cancer cell line PANC1, the colon cancer
cell line CaCo-2, and a transporter associated with antigen
processing (TAP)-deficient and HLA-A2 (A*02:01)-positive cell
line T2 were purchased from the Riken Cell Bank (Tsukuba,
Japan). The human liver cancer cell line SKHep1 and the human
pancreatic cancer cell line PK9 were provided by Dr Kyogo Itoh
(Kurume University, Kurume, Japan) and the Cell Resource Center
for Biomedical Research Institute of Development, Aging and
Cancer (Tohoku University, Sendai, Japan), respectively.
The expression of HLA-A2 was examined by flow cytometry
with an anti-HLA-A2 monoclonal antibody (mAb), BB7.2 (One
Lambda Inc., Canoga Park, CA, USA) to select HLA-A2-positive
blood donors and target cancer cell lines.
Patients, blood samples, and tumour tissues
The clinical research using peripheral blood mononuclear cells
(PBMCs) obtained from healthy donors was approved by the
Institutional Review Board of the Kumamoto University. The
cancer and adjacent non-cancerous tissues were obtained from 14
patients during routine diagnostic procedures from patients in the
Kumamoto University Hospital. The tissues were subjected to
either reverse transcription–PCR (RT–PCR) or immunohisto-
chemical analyses as listed in Table 1. Blood and tissue samples
were obtained from donors and patients, respectively, after
receiving their written informed consent.
RT–PCR
Reverse transcription–PCR analyses were performed as described
previously (Nakatsura et al, 2004a). The primers used were:
KIF20A, sense 50-CTACAAGCACCCAAGGACTCT-30 (788-808, the
4th exon) and antisense 50-AGATGGAGAAGCGAATGTTT-30
(1400-1381, the 8th exon) and ACTB, sense 50-CATCCACGAAACT
ACCTTCAACT-30 (903-925, the 5th exon) and antisense
50-TCTCCTTAGAGAGAAGTGGGGTG-30 (1535-1513, the 6th exon).
Primer positions are shown according to cDNA sequences
presented in the Gene Bank Accession numbers of NM_005733
for human KIF20A and of NM_001101 for human ACTB. The
products were 612bp long for KIF20A and 632bp long for ACTB.
After normalisation by the intensity for ACTB mRNA, the
expression levels of KIF20A mRNA were compared among the
tissues and cell lines.
Western blot analysis and immunohistochemical
examination
Western blot analysis and immunohistochemical staining of
KIF20A using rabbit polyclonal anti-KIF20A antibody (category
no. A300-879A) of Bethyl Laboratories (Montgomery, TX, USA)
were performed as described previously (Nakatsura et al, 2001;
Yoshitake et al, 2004). Immunohistochemical staining of CD4 or
CD8 in tissue specimens of HLA-A2 Tgm immunised with the
KIF20A-8809–817 peptide was performed as described previously
(Matsuyoshi et al, 2004).
Table 1 Expression of the KIF20A gene or protein in pancreatic cancer
tissues
Patient RT–PCR IHC
1  
a NT
2  
a  
3  
a  
b
4+
a NT
5+
a +
b
6+
a +
b
7+
a NT
8+
a NT
9+
a +
b
10 +
a NT
11 NT +
12 NT +
13 NT +
14 NT  
Abbreviations: IHC¼immunohistochemical analysis;  ¼negative; NT¼not tested;
+¼positive; RT–PCR¼reverse transcription–PCR.
aRT–PCR data are shown in
Figure 2.
bImmunohistochemical data are shown in Figure 3.
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Figure 1 The relative expression ratio of KIF20A mRNA in pancreatic
cancer tissues (Pancreatic Ca) and in various normal tissues based on a
cDNA microarray analysis. The KIF20A gene was overexpressed in all six
pancreatic cancer tissues investigated, but barely expressed in many normal
tissues, except for in the testis and thymus. The ratio of relative expression
levels of KIF20A mRNA in six pancreatic cancer tissues to that of disease-
free counterparts was calculated. For normal tissues, the average
expression level of KIF20A mRNA in all tissues was assigned to be 1.0,
and the relative expression level of KIF20A mRNA in each tissue was
calculated. For pancreatic cancer, the expression levels of KIF20A mRNA in
adjacent normal pancreatic tissues were assigned to be 1.0, and the relative
expression levels of KIF20A mRNA in pancreatic cancers were calculated
using specimens obtained from six patients with pancreatic cancer.
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KIF20A cDNA was transduced into SKHep1 cells by a lentiviral
vector-mediated gene transfer as described previously (Tahara-
Hanaoka et al, 2002; Irie et al, 2006). The expression of KIF20A
was confirmed by western blot analysis.
Induction and response of KIF20A-reactive mouse CTLs
A total of 36 human KIF20A-derived peptides (purity 495%) with
predicted high binding scores for HLA-A2 (A*02:01) by BIMAS
software (NIH, Bethesda, MD, USA; http://www-bimas.cit.nih.gov/)
were synthesised by the American Peptide Company (Sunnyvale,
CA, USA; Supplementary Table 1). The HLA-A2 Tgm were
immunised intraperitoneally twice on days 0 and 7 with bone
marrow-derived dendritic cells (BM-DCs) pulsed with 12 sets of a
mixture of 3 kinds of the 36 synthesised peptides. Seven days after
the last immunisation, CD4-depleted spleen cells (CD4
  spleen
cells) from Tgm using CD4 microbeads (Miltenyi Biotec, Auburn,
CA, USA) were stimulated in vitro with BM-DCs pulsed with each
peptide. The CTL responses to the peptides were tested by the
ELISPOT assay (human INF-g ELISPOT kit, BD Biosciences,
Franklin Lakes, NJ, USA).
Induction of KIF20A-reactive human CTLs
Peripheral monocyte-derived DCs were generated from CD14
þ
cells isolated from PBMCs of HLA-A2-positive healthy donors
using CD14 microbeads (Miltenyi Biotec), with stimulation of
100ngml
 1 granulocyte/macrophage colony-stimulating factor,
10ngml
 1 interleukin (IL)-4, and Streptococcal OK-432 (Picibanil,
Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) (Naito et al, 2006)
as described previously (Harao et al, 2008). The cells were
morphologically changed to express many dendrites, and their
expression levels of MHC class-II and CD80 were upregulated after
the stimulation with OK-432. The DCs were pulsed with 20mgml
 1
candidate peptides in the presence of 4mgml
 1 b2-microglobulin
Table 2 Expression of the KIF20A gene in pancreatic cancer and various
malignancies investigated by cDNA microarray analyses
a
N
Positive
rate
a (%)
Average of relative
expression ratio
Pancreatic cancer 6/6 100 31900
Small cell lung cancer 15/15 100 22
Bladder cancer 30/31 97 20500
Non-small cell lung cancer 20/22 91 25800
Cholangiocellular carcinoma 7/11 64 3780
Breast cancer 29/61 44 322
Prostate cancer 11/36 31 4
Renal cell carcinoma 3/11 27 5
Oesophageal cancer 2/13 15 3
Colorectal cancer 2/31 3 2
Gastric cancer 0/4 0 0
Data are obtained from our previous studies (Nakao et al, 1995; Uchida et al, 2004;
Yoshitake et al, 2004; Taniuchi et al, 2005; Watanabe et al, 2005).
aThe relative
expression ratio was calculated by dividing the value of the expression of KIF20A
mRNA in cancer cells by that in the normal counterpart, and a relative expression
ratio (cancer/normal tissue) of 45 was considered to be positive.
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Figure 2 Expression of KIF20A mRNA and protein in human normal tissues, cancer cell lines, and pancreatic cancer tissues. (A) RT–PCR analysis of
KIF20A mRNA expression in various normal tissues. KIF20A mRNA was not detected except for faint expression observed in the testis. (B) The expression
of KIF20A mRNA and protein in various cancer cell lines investigated by RT–PCR (left) and western blot analyses (right). KIF20A mRNA was detected in all
pancreatic cancer cell lines examined. The major bands at B100kDa, which corresponds to the calculated molecular weight for KIF20A, are shown. It must
be noted that SKHep1 and SKHep1/Mock expressed only a trace amount of the KIF20A protein, whereas KIF20A cDNA-transfected SKHep1, SKHep1/
KIF20A, relatively expressed a large amount of the protein. (C) RT–PCR analyses of the KIF20A expression in pancreatic cancer tissues (T), and their normal
counterparts (N). The expression of the KIF20A mRNA was detected in five of eight pancreatic tumour tissues, but little expression was detected in their
normal counterparts. It must be noted that KIF20A mRNA expression was also detected in the peritoneum (patient 9 (Pt9)) and metastatic foci of the skin
(patient 10 (Pt10)).
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s(Sigma-Aldrich, St Louis, MO, USA) for 2h at 371C in AIM-V
medium (Invitrogen, Carlsbad, CA, USA) containing 2% auto-
logous plasma. The DCs were then irradiated (40Gy) and
incubated with CD8
þ cells isolated from the same PBMCs using
CD8 microbeads (Miltenyi Biotec). These cultures were set up in
24-well plates; each well contained 1 10
5 peptide-pulsed DCs,
2 10
6 CD8
þ T cells, and 5ngml
 1 human IL-7 (Wako, Osaka,
Japan), in 2ml AIM-V with 2% autologous plasma. After 2 days,
these cultures were supplemented with human IL-2 (PeproTec,
Rocky Hill, NJ, USA) to a final concentration of 20IUml
 1. Two
additional stimulations with peptide-loaded autologous DCs were
carried out on days 7 and 14. Six days after the last stimulation,
antigen-specific CTL responses were investigated by the ELISPOT
assay and the
51Cr release assay as described previously (Komori
et al, 2006).
CTL responses against cancer cell lines
Human CTLs were co-cultured with cancer cells or peptide-pulsed
T2 cells as a target (5 10
3 per well) at the indicated effector/target
ratio, and a standard
51Cr release assay was performed (Komori
et al, 2006). An HLA-A2 (A*02:01)-binding HIV-derived peptide,
SLYNTVATL, was used as an irrelevant control peptide (Parker
et al, 1992). Blocking of HLA-class I or HLA-DR in the ELISPOT
assay was performed as follows: the target cancer cells were
incubated with 10mgml
 1 anti-HLA-class I mAb, W6/32, or
10mgml
 1 anti-HLA-DR mAb, H-DR-1 (kindly provided by
Dr Kyogo Itoh (Nakao et al, 1995)) for 1h before co-culture with
CTLs, and the inhibitory effects of mAbs on the production of
IFN-g by CTLs were monitored (Gomi et al, 1999).
RESULTS
Identification of the KIF20A gene upregulated in
pancreatic cancer and various malignancies based
on cDNA microarray analyses
Using genome-wide cDNA microarray analyses, it turned out that
six genes, namely CDH3, KIF20A, MICAL2, TRIM29, ABHD, and
EPHA4, were overexpressed in the six pancreatic cancer tissues in
comparison with their adjacent normal counterparts, and we
reported that CDH3/P-cadherin is a new TAA for immunotherapy
of pancreatic, gastric, and colorectal cancers (Imai et al, 2008). In
this study, we focused on KIF20A as another pancreatic cancer-
specific TAA for immunotherapeutic target. The cDNA microarray
analyses revealed that expression of the KIF20A gene in pancreatic
cancer tissues was markedly enhanced in all six patients
investigated (the average of the relative expression ratio: 31900,
ranging 15–72000), whereas the KIF20A gene was faintly
expressed only in the testis and thymus among normal tissues
(Figure 1). In addition, overexpression of the KIF20A gene was also
observed in other malignancies, such as lung and bladder cancers
(Table 2) (Kitahara et al, 2001; Hasegawa et al, 2002; Kikuchi et al,
2003; Nakamura et al, 2004; Obama et al, 2005) .
Expression of KIF20A mRNA and protein in normal
organs, cancer cell lines, and pancreatic cancer tissues
The expression of the KIF20A gene in normal tissues was analysed
by RT–PCR analyses, which revealed its exclusive expression in
the testis and thymus (Figure 2A). On the other hand, the
expression of the KIF20A gene was detected in almost all
Patient 6 Patient 5
Patient 9
(intraperitoneal dissemination)
Tumour-forming
pancreatitis
Skin Testis
Stomach Colon
Brain Lung
Spleen
Kidney Liver
Small intestine
Thymus
Patient 3
Figure 3 Immunohistochemical analyses of the KIF20A protein in (A) pancreatic cancer and in (B) various normal tissues. (Panel A) A strong staining of
KIF20A was mainly observed at the cytoplasm and nuclei of cancer cells in six of nine cases (representative patients 5, 6, and 9 are shown), whereas a very
weak staining was observed in acinar cells and in the normal ductal epithelium of their normal adjacent pancreatic tissues. A pancreatic cancer tissue without
KIF20A expression is also shown (Patient 3). A similar strong staining was observed in the metastatic foci of the peritoneum (Patient 9). (Panel B) KIF20A
was not detected in the normal brain, lung, liver, kidney, stomach, small intestine, colon, spleen, skeletal muscle, skin, thymus, and testis. Little staining was
detected in tumour-forming pancreatitis. Positive staining signals are seen as brown. The scale bars represent 100mm.
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(Figure 2B, left). Those observations essentially coincided with
data obtained by cDNA microarray analyses.
We then checked the expression of the KIF20A gene in surgically
resected pancreatic cancer tissues and their adjacent normal
counterparts by RT–PCR analyses. The KIF20A gene was detected
in five of eight pancreatic cancer tissues, whereas virtually no
expression was observed in their normal counterparts (Figure 2C).
It is noteworthy that KIF20A was also detected in the metastatic
foci of the skin and peritoneum.
Western blot analysis revealed expression of the KIF20A
protein in various HLA-A2
þ cancer cell lines tested, except for
SKHep1 (Figure 2B, right). To confirm the tumour-associated
overexpression of the KIF20A protein, various paraffin-embedded
normal tissue specimens and pancreatic cancer specimens were
examined by immunohistochemical analyses. We investigated nine
samples of pancreatic cancer (Table 1), and a strong staining of
KIF20A was mainly observed in the cytoplasm and nuclei of cancer
cells in six cases, whereas a very weak staining was observed in
acinar cells and the normal ductal epithelium of their normal
adjacent pancreatic tissues (Figure 3A). Little staining was detected
in tumour-forming pancreatitis. KIF20A was not detected in the
normal brain, lung, liver, kidney, stomach, small intestine, colon,
spleen, skeletal muscle, skin, thymus, and skin (Figure 3B).
Therefore, the pattern of KIF20A protein expression essentially
paralleled with its gene expression profile.
Identification of KIF20A-derived and HLA-A2-restricted
mouse CTL epitopes using HLA-A2 Tgm
A total of 36 peptides with high binding scores to HLA-A2
(A*02:01) by BIMAS (Supplementary Table 1) were immunised
to HLA-A2 Tgm, and CD4
  spleen cells were stimulated in vitro
with BM-DCs pulsed with each peptide. The CD4
  spleen cells
stimulated with KIF20A-2 (p12–20, LLSDDDVVV), KIF20A-8
(p809–817, CIAEQYHTV), and KIF20A-28 (p284–293,
AQPDTAPLPV) peptides produced a significant amount of INF-g
in a peptide-specific manner in the ELISPOT assay (Figure 4A).
Those CD4
  spleen cells (2 10
4) showed 149.0±22.2,
117.2±23.4, and 141.2±5.5 spot counts per well in response to
BM-DCs pulsed with the KIF20A-2, KIF20A-8, and KIF20A-28
peptides, respectively, whereas they showed 32.6±9.9, 51.4±7.8,
and 19.2±5.2 spot counts per well, respectively, without peptide
loading (Po0.01). No significant peptide-specific response was
observed with the other peptides. These results suggest that the
KIF20A-2, KIF20A-8, and KIF20A-28 peptides could be the
HLA-A2-restricted CTL epitope peptides in HLA-A2 Tgm and
those peptides were expected to be epitopes for human CTLs.
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Figure 4 Identification of HLA-A2-restricted mouse CTL epitopes of human KIF20A using HLA-A2 Tgm. (A) HLA-A2 Tgm were immunised with
syngeneic BM-DCs pulsed with the peptide mixtures as described in the ‘Materials and Methods’ section, and CD4
  spleen cells were stimulated with
BM-DCs pulsed with or without each peptide for 6 days. INF-g-producing CTLs were detected by an ELISPOT assay. KIF20A-2 (LLSDDDVVV), KIF20A-8
(CIAEQYHTV), and KIF20A-28 (AQPDTAPLPV) peptides indicated by the circles were shown to induce peptide-reactive CTLs. These assays were
performed twice with similar results. (B) Immunohistochemical staining with anti-CD4 or anti-CD8 mAb in tissue specimens of HLA-A2 Tgm immunised
with the KIF20A-8 peptide. After two-times vaccinations, these specimens were removed and analysed.
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Figure 5 Induction of KIF20A-specific human CTLs from PBMCs of three HLA-A2-positive healthy donors. (A) KIF20A peptide-reactive CTLs generated
from PBMCs of three HLA-A2-positive healthy donors effectively killed T2 cells (HLA-A2
þ, TAP deficient) pulsed with each peptide but not those unpulsed
or pulsed with irrelevant and HLA-A2-restricted CTL epitopes of HIV. (B) Human CTLs exhibited cytotoxicity to the KIF20A
þ, HLA-A2
þ human
pancreatic cancer cell line PANC1 and to the colon cancer cell line CaCo-2, but not to KIF20A
þ, HLA-A2
  human pancreatic cancer cell line PK9. (C) The
cytotoxicity of human CTLs was KIF20A specific. Those CTLs killed SKHep1/KIF20A, but not mock-transfected SKHep1 cells. Representative data are
shown. (D) Human CTL responses were inhibited by anti-HLA-class I mAb (W6/32, IgG2a) but not by anti-HLA-DR mAb (H-DR-1, IgG2a). The target cells
used were PANC-1cell (KIF20A
þ, HLA-A2
þ) and PK9 cell (KIF20A
þ, HLA-A2
 ). (Panels A–D) Representative data from one of the three donors with
similar results are shown.
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with KIF20A-8 in HLA-A2 Tgm
Whether immunisation with KIF20A peptides induces auto-
immune reactions is of great importance. The immunohistochem-
ical analyses of several vital organs with anti-CD4 and anti-CD8
mAbs were performed in HLA-A2 Tgm after two-times vaccination
with the KIF20A-8 peptide, as its amino-acid sequence was
identical between human and mouse KIF20A. As shown in
Figure 4B, no pathological change that suggests autoimmunity,
such as lymphocyte infiltration or tissue destruction, was
observed, indicating that lymphocytes stimulated with the
KIF20A-8 peptide were safe at least in HLA-A2 Tgm.
Induction of KIF20A-reactive human CTLs from PBMCs of
HLA-A2-positive healthy donors
To investigate whether the KIF20A-2, KIF20A-8, and KIF20A-28
peptides could generate KIF20A-specific human CTLs, CD8
þ
T cells sorted from PBMCs of HLA-A2-positive healthy donors
were incubated with the autologous CD14
þ cell-derived DCs
pulsed with each peptide. After three-times stimulations, the
cytotoxic activities of CD8
þ T cells against peptide-pulsed
T2 cells were examined by the
51Cr release assay (Figure 5A).
Each CTL killed the T2 cells pulsed with KIF20A-2 (left), KIF20A-8
(middle), or KIF20A-28 (right) peptides, but not the T2 cells
pulsed with irrelevant HLA-A2-binding HIV peptide or those
without peptide loading. The data indicate that KIF20A peptides
successfully induced human CTLs with peptide-specific cyto-
toxicity.
Next, the capacity of these CTLs to kill human cancer cell lines
expressing both KIF20A and HLA-A2 was examined. As shown in
Figure 5B, KIF20A-reactive CTLs stimulated with KIF20A-2 (left),
KIF20A-8 (middle), or KIF20A-28 (right) peptides exhibited
effective cytotoxicity to PANC1 (KIF20A
þ,H L A - A 2
þ) and CaCo-2
(KIF20A
þ, HLA-A2
þ), but not to PK9 (KIF20A
þ, HLA-A2
 ).
Furthermore, all CTLs exhibited cytotoxicity against SKHep1/
KIF20A (KIF20A
þ, HLA-A2
þ), SKHep1 cells (KIF20A
 , HLA-A2
þ)
transfected with the KIF20A gene (Figure 2B, right), but not against
SKHep1/Mock, SKHep1 cells transfected with an empty vector
(Figure 5C). Those results suggested that CTL responses were
specific to KIF20A expression and that the epitope peptides were
naturally processed and expressed on the surface of cancer cells in
the context of HLA-A2 molecules.
Blocking mAb specific to HLA-class I (W6/32) markedly
reduced the number of INF-g-producing CTLs generated by
stimulation with KIF20A-2 (left), KIF20A-8 (middle), or KIF20A-
28 (right) peptides by co-culture with PANC1 cells with statistical
significance (Figure 5D, Po0.01), whereas anti-HLA-DR mAb
(H-DR-1) had no effect on CTL responses. The data verified that
CTLs recognised KIF20A-expressing target cells in an HLA-class
I-restricted manner.
DISCUSSION
In this study, whether KIF20A is applicable to a target of
anticancer immunotherapy was carefully investigated. The KIF20A
gene was overexpressed in pancreatic cancer cells but barely
expressed in their normal counterparts and in many normal adult
tissues as revealed by the cDNA microarray analysis, RT–PCR
analysis, and immunohistochemical analyses. As a weak expres-
sion of KIF20A in the normal thymus in addition to the testis was
observed in the cDNA microarray and RT–PCR analyses, KIF20A
is not a perfect cancer/testis antigen but a TAA overexpressed in
pancreatic cancer, as well as in bladder cancer, non-small cell lung
cancer, and cholangiocellular carcinoma. We have reported that
CDH3/P-cadherin is another TAA that is overexpressed in
pancreatic cancer (Imai et al, 2008); however, it has been often
observed that using a single TAA as a target of anticancer
immunotherapy does not yield satisfactory therapeutic outcomes
in animal models. Using multiple TAAs in combination as targets
drastically improved the outcome of anticancer immunotherapy
(Fukushima et al, 2009), and therefore KIF20A could be not only a
versatile tumour marker but also a TAA useful as a target of
anticancer immunotherapy for pancreatic cancer by itself or in
combination with other TAA(s). Furthermore, the involvement of
KIF20A in pancreatic carcinogenesis suggests that KIF20A would
be a promising immunotherapeutic target for pancreatic cancer as
described below.
The KIF20A protein, also known as RAB6KIFL/MKlp2, was first
identified to localise to Golgi apparatus and to have an important
role in the dynamics in this organelle by an interaction with the
GTP-bound form of Rab6 (Echard et al, 1998). KIF20A belongs to a
large family of motor proteins that accumulate in mitotic cells, and
microinjection of anti-KIF20A antibodies resulted in the failure of
cytokinesis (Hill et al, 2000). The knockdown of KIF20A gene
expression in pancreatic cancer cell lines by small-interfering RNA
drastically inhibited the growth of those cells (Taniuchi et al,
2005).
The potential CTL target epitopes of KIF20A were listed among
the HLA-A2 (A*02:01) binders predicted by the BIMAS software
and surveyed using HLA-A2 Tgm. All three candidate epitope
peptides identified could stimulate the generation of human CTLs
that showed KIF20A-specific cytotoxicity in an HLA-A2-restricted
manner in all three individuals examined. Importantly, immunisa-
tion of the KIF20A-8 peptide, of which the amino-acid sequence is
conserved between human and mouse KIF20A, did not induce any
signs of autoimmune phenomenon, suggesting the safety of this
peptide for using anticancer immunotherapy targeting KIF20A. In
this sense, the HLA-A2 is not only a powerful tool for rapid
identification of HLA-A2-restricted CTL epitopes but also for
evaluating the in vivo outcomes of immunotherapy using epitope
peptides.
In conclusion, our data showed that KIF20A is a novel TAA
and a potential target for anticancer immunotherapy for cancer
cells expressing KIF20A at least in an HLA-A2-restricted situation.
As KIF20A is highly expressed in a wider range of human
malignancies, KIF20A is therefore a promising target for peptide-
based immunotherapy for the treatment of malignancies, espe-
cially pancreatic cancer. Further investigation of the capability
for induction of KIF20A-specific CTLs in pancreatic cancer
patients thus remains an issue of great importance for clinical
application.
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